Fig. 7
From: Challenges and strategies associated with CAR-T cell therapy in blood malignancies
Strategies for modulating the Tumor Microenvironments. A: Targeting suppressive cell types. Using monoclonal antibodies and CAR-T cells to eliminate immunosuppressive cells such as T regulatory cells (Tregs), myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs). B: Targeting suppressive cytokines. CAR-T cells targeting TGF-βinhibit the proliferative and anti-tumor abilities of cytotoxic cells. C: Targeting inhibitory signals. Genetic engineering technology that disrupts FAS signaling on T cells